Identification of novel inhibitors against Med15a KIX domain of Candida glabrata

Int J Biol Macromol. 2023 Dec 31;253(Pt 2):126720. doi: 10.1016/j.ijbiomac.2023.126720. Epub 2023 Sep 8.

Abstract

Candida glabrata, the second most common cause of invasive fungal infections, exhibits multi-drug resistance to commonly used antifungal drugs. To counter this resistance, there is a critical need for novel antifungals. This study identifies small molecule inhibitors that target a three-helix bundle KIX domain in the Med15a Mediator subunit of Candida glabrata (CgMed15a KIX). This domain plays a crucial role by interacting with the Pleiotropic Drug Resistance transcription factor Pdr1, a key regulator of the multidrug resistance pathway in Candida glabrata. We performed high throughput computational screening of large chemical datasets against the binding sites of the CgMed15a KIX domain to identify novel inhibitors. We selected six potential candidates with high affinity and confirmed their binding with the CgMed15a KIX domain. A phytochemical compound, Chebulinic acid binds to the CgMed15a KIX domain with a KD value of 0.339 μM and shows significant inhibitory effects on the growth of Candida glabrata. Molecular dynamics simulation studies further revealed the structural stability of the CgMed15a KIX-Chebulinic acid complex. Thus, in conclusion, this study highlights Chebulinic acid as a novel potential antifungal compound against Candida glabrata.

Keywords: Chebulinic acid; Med15a KIX domain; Molecular dynamic simulation.

MeSH terms

  • Antifungal Agents* / metabolism
  • Antifungal Agents* / pharmacology
  • Candida glabrata* / metabolism
  • Drug Resistance, Fungal
  • Hydrolyzable Tannins / pharmacology
  • Transcription Factors / metabolism

Substances

  • Antifungal Agents
  • chebulinic acid
  • Transcription Factors
  • Hydrolyzable Tannins